Profile
Janine Reudt-Demont is a life sciences and healthcare specialist at Niederer Kraft Frey. Her experience covers the regulation of all aspects of the medtech and pharmaceutical industry, including clinical trials, product classifications, authorizations, market access, promotion and marketing, compliance (including data privacy questions) as well as transparency and anti-corruption. Janine also advises on regulatory and compliance matters concerning other regulated products such as cosmetics, foodstuffs, tobacco and CBD-products.
Janine further possesses specialist knowledge and experience in all areas of commercial law, with main focus on distribution, franchising, e-commerce as well as product liability and product safety matters (including recalls). She also has an IP background and often advises on licensing, R&D and supply agreements as well as on unfair competition and advertising law.
In addition to her advisory expertise, Janine regularly represents clients in court proceedings, arbitration, mediation and before administrative bodies.
Experience
Recent matters in which Janine acted include advising/representing:
- The shareholders of Bahnhof Apotheke Langnau AG, the Swiss pioneer in cannabis formulations and treatments, on the sale of 100% of the shares to Galenica, one of the leading fully-integrated healthcare providers in Switzerland;
- Various manufacturers and distributors of medical devices on the implementation of the revised regulation on medical devices;
- One of the largest e-commerce retailers with respect to unfair competition, pricing and advertising;
- Neurimmune AG, a startup biopharmaceutical company, with respect to clinical studies, data protection and pharma advertising;
- A Belgian distributor of high-quality pacifiers and baby products on the termination of a long-term distribution contract and in negotiations for a goodwill compensation;
- Health Apps & Plattforms Speaker at NKF Client Event, 9 April 2024
- Produktehaftpflichtprozess: Die «Defence of Regulatory Compliance» in: Life Science Recht, March 2024, p. 143-150
- Cookies/Newsletter/Social Media Speaker at NKF Client Event, 8 February 2024
- The revised data protection act Speaker at NKF Client Event, 5 October 2023 and 7 November 2023
- Practical Implementation Steps for the revised Federal Act on Data Protection (FADP) Speaker at NKF Breakfast Event, 5 September 2023, Zurich
- Gesunder Wettbewerb: Biotechnologie trifft auf Kartellrecht in: Life Science Recht 3/2023, S. 162, August 2023
- Carve-out-Transaktionen und Asset Deals – Regulatorische Besonderheiten 2. Berner Tagung zum Life Science Recht, 14. Juni 2023
- Litigation / T.R.A.D.E. Commissions Speaker at AIJA in Munich, 22 June 2023
- Healthcare & Life Sciences and Antitrust Commissions Speaker at AIJA in Budapest, 27 April 2023
- Digitalisierung des Gesundheitswesens 2023 Life Science Recht 1/2023, S. 39, März 2023
- KI und MedTech: Welche Regulierungsvorschriften greifen und was sind die Herausforderungen? Schulthess Forum Digitalisierung im Gesundheitswesen, 17. Januar 2023
- Erste Erfahrungen mit der revidierten Medizinprodukteverordnung Life Science Recht 2/2022, S. 105, 3. Juni 2022
- The Healthcare Law Review: Switzerland, 2021 in: The Healthcare Law Review 2021, 5th Edition, Law Business Research Ltd., August 2021
- Virtual Hearings in Civil Trials and FINMA Proceedings in: Jusletter, 12. April 2021
- The Healthcare Law Review: Switzerland, 2020 in: The Healthcare Law Review 2020, 4th Edition, Law Business Research Ltd., September 2020
- AIJA IP&TMT QUESTIONNAIRE: Measures aimed at tracking and identifying individuals related to COVID-19 – Switzerland
- Bearbeiten von Patientendaten in Zeiten von COVID-19 aus Sicht der Gesundheitsbranche – Was ist zu beachten? Weblaw-Webinar, 21. April 2020
- Die neue Verordnung über klinische Versuche mit Medizinprodukten (KlinV-Mep) in: Life Science Recht 1/2020, S. 35-44, März 2020
- Revision des Medizinprodukterechts – Der Entwurf zur Totalrevision der Medizinprodukteverordnung in: Life Science Recht 4/2019, S. 239-247, November 2019
- Medicines and Medical Devices in the EU Single Market – Dreams and Reality in: Life Science Recht 4/2019, S. 270-273, November 2019
- ADR in IP disputes – with particular focus on employment matters in: IBA’s Intellectual Property and Entertainment Law Committee August 2019 Newsletter
- Eckpunkte der neuen Medizinprodukte-Regulierung in: Life Science Recht 3/2019, S. 183-191
- The New MDRs – impact on study agreements and distribution contracts AIJA Healthcare Seminar Zurich, 27-29 June 2019
- Growing friction between brand owners and (offline) resellers AIJA T.R.A.D.E. Seminar Athens, 11-13 April 2019
- Totalrevision der Verordnung über die Bewilligungen im Arzneimittelbereich in: Life Science Recht, 4/2018, S. 261-266
- Immaterialgüterrechte in Schiedsverfahren DIS40 Seminar Zurich, 9 October 2018
- MDR & IVDR: Auswirkungen auf die Schweiz Life Science Recht 3/2018, S. 208-212
- The sunset of the business: “How do I get rid of my contract” – ways to exit, terminate or set the scene to exit an agreement AIJA T.R.A.D.E. Seminar Amsterdam, 12-14 April 2018
- Code of Ethics and Conduct: Does setting your own rules to behave on the market work?, panel moderator AIJA T.R.A.D.E. Seminar Bratislava, 12-14 October 2017
- Distribution of pharmaceutical products: a changing environment?, panel moderator AIJA T.R.A.D.E. Seminar Bratislava, 12-14 October 2017
- Aktuelle Entwicklung in Rechtsprechung und Gesetzgebung in der Schweiz, 2017 Seminar “Aktuelle Entwicklungen im Bereich Life Sciences” of the Europe Institute at the University of Zurich (EIZ) on 3 October 2017
- Should you be a distributor, an agent or a franchisee – “beauty contest” AIJA conference, Tel Aviv 2016 Conference on “Litigating your distribution and agency contracts on an international scale”
- Distribution of regulated products – avoid pitfalls in litigation in: Leaders League, Innovation and Technology, 2016
- Aktuelle Entwicklungen in Rechtsprechung und Gesetzgebung in der Schweiz, 2015 Seminar “Aktuelle Entwicklungen im Bereich Life Sciences” of the Europe Institute at the University of Zurich (EIZ) on 29 October 2015
- Vorsorgliche Beweisführung im Produktehaftpflichtprozess: Ermöglichung einer unerwünschten Präjudizwirkung für das Hauptverfahren? in: HAVE/REAS 3/2014, S.308-312
- Advisory Board des Informa MedTech Summit
- Association Internationale des Jeunes Avocats (AIJA), President of the Healthcare and Life Sciences Commission, former National Representative for Switzerland and former Vice-President of the T.R.A.D.E. (Trade, Retail, Agency, Distribution, E-Commerce) Commission
- International Distribution Institute (IDI)
- Licensing Executives Society (LES)
- Swiss Bar Association
- Zurich Bar Association
German
English
French
Italian